Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Viking Therapeutics shares rose Monday morning before reversing course and declining after reporting the latest results from ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

VK2735 is a dual GLP-1/GIP receptor agonist similar to Eli Lilly's (LLY) blockbuster weight loss drug Zepbound, designed to ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals ... It consists of the company's weight loss drugs: Mounjaro, approved for type 2 diabetes but also prescribed off-label for weight ...

Company behind weight loss drug Mounjaro, Lilly, has issued an official statement after British woman, Susan McGowan, died ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage ...

Beyond weight loss, the semaglutide group experienced ... Image: Scott Olson / Staff (Getty Images) Eli Lilly (LLY) said in August that the drug behind Zepbound was found to help nearly eliminate ...